

Kerstin Rhiem

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7022512/publications.pdf>

Version: 2024-02-01

68
papers

3,883
citations

186265

28
h-index

128289

60
g-index

75
all docs

75
docs citations

75
times ranked

5901
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of aging and gadolinium exposure on T1, T2, and T2*-relaxation in healthy women with an increased risk of breast cancer with and without prior exposure to gadoterate meglumine at 3.0-T brain MR imaging. <i>European Radiology</i> , 2022, 32, 331-345.	4.5	3
2	Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors. <i>Breast Care</i> , 2022, 17, 208-223.	1.4	6
3	Medical knowledge and information needs among women with pathogenic variants in moderate-risk genes for hereditary breast cancer attending genetic counseling at an academic hospital in Germany – A qualitative approach. <i>Journal of Genetic Counseling</i> , 2022, 31, 698-712.	1.6	4
4	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. <i>European Journal of Cancer</i> , 2022, 160, 100-111.	2.8	12
5	Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. <i>Cancers</i> , 2022, 14, 521.	3.7	12
6	Nurse-led decision coaching by specialized nurses for healthy BRCA1/2 gene mutation carriers – adaptation and pilot testing of a curriculum for nurses: a qualitative study. <i>BMC Nursing</i> , 2022, 21, 42.	2.5	4
7	Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial. <i>Trials</i> , 2022, 23, 157.	1.6	7
8	“You Always Have It in the Back of Your Mind” – Feelings, Coping, and Support Needs of Women with Pathogenic Variants in Moderate-Risk Genes for Hereditary Breast Cancer Attending Genetic Counseling in Germany: A Qualitative Interview Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3525.	2.6	2
9	Assessment of psychosocial difficulties by genetic clinicians and distress in women at high risk of breast cancer: a prospective study. <i>European Journal of Human Genetics</i> , 2022, 30, 1067-1075.	2.8	2
10	Genetic clinicians' confidence in BOADICEA comprehensive breast cancer risk estimates and counselees' psychosocial outcomes: A prospective study. <i>Clinical Genetics</i> , 2022, 102, 30-39.	2.0	3
11	Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review. <i>Value in Health</i> , 2021, 24, 303-312.	0.3	16
12	Modern day screening for Lynch syndrome in endometrial cancer: the KEM experience. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 975-984.	1.7	3
13	Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neoadjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 506-506.	1.6	96
14	Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 180.	3.0	18
15	Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 679-698.	1.8	4
16	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. <i>Lancet Oncology</i> , The, 2021, 22, 1151-1161.	10.7	248
17	Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation – real life data. <i>Gynecologic Oncology</i> , 2021, 163, 569-577.	1.4	7
18	Breast cancer characteristics and surgery among women with Li-Fraumeni syndrome in Germany – A retrospective cohort study. <i>Cancer Medicine</i> , 2021, 10, 7747-7758.	2.8	7

#	ARTICLE	IF	CITATIONS
19	Risk-Adjusted Prevention. Perspectives on the Governance of Entitlements to Benefits in the Case of Genetic (Breast Cancer) Risks. <i>Recent Results in Cancer Research</i> , 2021, 218, 47-66.	1.8	2
20	The ticking time-bomb. Health literacy in the context of genetic risk prediction in familial breast-ovarian cancer; A qualitative study. <i>Qualitative Research in Medicine & Healthcare</i> , 2021, 5, .	0.2	5
21	Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany. <i>Breast Care</i> , 2021, 16, 389-395.	1.4	0
22	Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany. <i>Breast Care</i> , 2021, 16, 389-395.	1.4	3
23	Breast cancer risk in <i>BRCA1/2</i> mutation carriers and noncarriers under prospective intensified surveillance. <i>International Journal of Cancer</i> , 2020, 146, 999-1009.	5.1	32
24	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> Mutations in Patients with Primary Ovarian Cancer – Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 932-940.	1.8	7
25	Cancer surveillance and distress among adult pathogenic <i>TP53</i> germline variant carriers in Germany: A multicenter feasibility and acceptance survey. <i>Cancer</i> , 2020, 126, 4032-4041.	4.1	20
26	Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 744.	7.1	42
27	Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. <i>European Journal of Cancer</i> , 2020, 130, 92-101.	2.8	26
28	The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance. <i>Current Medical Research and Opinion</i> , 2019, 35, 2103-2110.	1.9	4
29	Biallelic germline <i>BRCA1</i> mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e863.	1.2	22
30	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in <i>BRCA2</i> Mutation Carriers. <i>European Urology</i> , 2019, 76, 831-842.	1.9	148
31	Residual glandular tissue (RGT) in <i>BRCA1/2</i> germline mutation carriers with unilateral and bilateral prophylactic mastectomies. <i>Surgical Oncology</i> , 2019, 29, 126-133.	1.6	20
32	Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classification. <i>Human Mutation</i> , 2019, 40, 1557-1578.	2.5	102
33	Germline loss-of-function variants in the <i>BARD1</i> gene are associated with early-onset familial breast cancer but not ovarian cancer. <i>Breast Cancer Research</i> , 2019, 21, 55.	5.0	44
34	Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort. <i>Breast Journal</i> , 2019, 25, 455-460.	1.0	35
35	Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer. <i>European Journal of Health Economics</i> , 2019, 20, 739-750.	2.8	16
36	High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 217-228.	2.5	94

#	ARTICLE	IF	CITATIONS
37	Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer – an European consensus statement and expert recommendations. <i>European Journal of Cancer</i> , 2019, 106, 54-60.	2.8	25
38	Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto – GBG 84): A randomised phase III trial. <i>European Journal of Cancer</i> , 2019, 106, 181-192.	2.8	84
39	GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2019, 37, 506-506.	1.6	34
40	Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 509-509.	1.6	10
41	Gene panel testing of 5589 <i>BRCA1/2</i> negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. <i>Cancer Medicine</i> , 2018, 7, 1349-1358.	2.8	126
42	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	2.5	224
43	Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a <i>BRCA 1</i> or <i>2</i> mutation. <i>European Journal of Health Economics</i> , 2018, 19, 341-353.	2.8	30
44	Individuals with <i>FANCM</i> biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. <i>Genetics in Medicine</i> , 2018, 20, 452-457.	2.4	59
45	Non-small cell neuroendocrine carcinoma of the ovary in a <i>BRCA2</i> -germline mutation carrier: A case report and brief review of the literature. <i>Oncology Letters</i> , 2018, 15, 4093-4096.	1.8	10
46	A tandem duplication of <i>BRCA1</i> exons 19 through <i>DHX8</i> exon 2 in four families with hereditary breast and ovarian cancer syndrome. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 561-569.	2.5	12
47	<i>BRIP1</i> loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 7.	5.0	78
48	Prevalence of pathogenic <i>BRCA1/2</i> germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. <i>BMC Cancer</i> , 2018, 18, 265.	2.6	84
49	Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 104-104.	1.6	43
50	Germline Mutations in Triple-Negative Breast Cancer. <i>Breast Care</i> , 2017, 12, 15-19.	1.4	59
51	Association Between Loss-of-Function Mutations Within the <i>FANCM</i> Gene and Early-Onset Familial Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1245.	7.1	74
52	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1378.	7.1	300
53	A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3062-3062.	1.6	11
54	Prevalence of <i>BRCA1/2</i> germline mutations in 21401 families with breast and ovarian cancer. <i>Journal of Medical Genetics</i> , 2016, 53, 465-471.	3.2	179

#	ARTICLE	IF	CITATIONS
55	Vacuum-assisted breast biopsies (VAB) carried out on an open 1.0 T MR imager: Influence of patient and target characteristics on the procedural and clinical results. <i>European Journal of Radiology</i> , 2016, 85, 1157-1166.	2.6	6
56	<i>BRCA1/2</i> mutation prevalence in triple-negative breast cancer patients without family history of breast and ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1090-1090.	1.6	2
57	Effect of distress and personality factors on the preference-sensitive decision making of <i>BRCA1/2</i> mutation carriers on preventive options.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1589-1589.	1.6	1
58	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	5.0	26
59	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	7.4	390
60	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	2.5	22
61	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	3.5	47
62	Supplemental screening ultrasound increases cancer detection yield in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 663-670.	1.7	22
63	Genome-Wide Association Study in <i>BRCA1</i> Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	3.5	244
64	The risk of contralateral breast cancer in patients from <i>BRCA1/2</i> negative high risk families as compared to patients from <i>BRCA1</i> or <i>BRCA2</i> positive families: a retrospective cohort study. <i>Breast Cancer Research</i> , 2012, 14, R156.	5.0	112
65	Hereditary Breast and Ovarian Cancer. <i>Deutsches Arzteblatt International</i> , 2011, 108, 323-30.	0.9	119
66	Contralateral Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2009, 27, 5887-5892.	1.6	292
67	Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: A prospective cohort study. <i>Gynecologic Oncology</i> , 2006, 103, 1077-1082.	1.4	53
68	<i>BRCA1</i> -Associated Breast Carcinomas Frequently Present with Benign Sonographic Features. <i>American Journal of Roentgenology</i> , 2006, 186, E11-E12.	2.2	24